Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
The researcher want to study compounds present in the skin, which may increase blood vessel formation. This is important because if certain compounds are increased in these skin lesions which help promote blood vessel formation and growth of skin lesions, these compounds may be the targets of future treatments. Future medications may be able to directly target these compounds in order to slow blood vessel formation and treat certain skin conditions.
|Study Design:||Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target|
- expression of various angiogenic factors in dermatologic diseases. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||November 2008|
|Estimated Study Completion Date:||January 2016|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Other: dermatologic diseases
Other Name: dermatologic diseases
Subjects who agree to participate will have one or more of their skin lesions biopsied. Such biopsies would be done the same way they would be done in clinic by your regular dermatologist. Additionally, normal skin biopsied as well so the researcher can compare normal skin to the skin lesion.
The biopsy specimen will be processed by doctors in the UC Irvine Dermatopathology Department and prepare the biopsy specimen for testing. The researcher want to do specific tests on the biopsy in order to study the compounds in the skin lesion.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00842283
|United States, California|
|Beckman Laser Institute Medical clinic|
|Irvine, California, United States, 92612|
|Principal Investigator:||Kristen Kelly, MD||Beckman Laser Institute University of California Irvine|